ABBV-400, an anti-MET ADC linked to a topoisomerase I inhibitor, is in phase 1 testing for EGFR-WT NSQ NSCLC patients who progressed after platinum, immunotherapy, or targeted therapy [52]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.